^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
huCART19-IL18
i
Other names: huCART19-IL18
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
University of Pennsylvania
Drug class:
CD19-targeted CAR-T immunotherapy, IL-18 stimulant
Related drugs:
6ms
TmCD19-IL18 in CD19+ Cancers (clinicaltrials.gov)
P1, N=24, Recruiting, University of Pennsylvania | Not yet recruiting --> Recruiting
Enrollment open • CAR T-Cell Therapy
|
ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
|
CD19 expression • BCL6 rearrangement • BCL2 rearrangement
|
huCART19-IL18
9ms
TmCD19-IL18 in CD19+ Cancers (clinicaltrials.gov)
P1, N=24, Not yet recruiting, University of Pennsylvania
New P1 trial • CAR T-Cell Therapy
|
ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6) • IGH (Immunoglobulin Heavy Locus) • IL18 (Interleukin 18)
|
CD19 expression • BCL6 rearrangement • BCL2 rearrangement
|
huCART19-IL18
Share via
